Ovarian Ablation in Breast Cancer Patients and the Possibility of Influencing Treatment Side Effects
Authors:
M. Palacova
Authors place of work:
Klinika komplexní onkologické péče, Masarykův onkologický ústav, Brno
Published in the journal:
Klin Onkol 2016; 29(Supplementum 3): 29-38
Category:
Review
doi:
https://doi.org/10.14735/amko20163S29
Summary
Ovarian suppression or ovarian ablation used in treatment of breast carcinoma results in temporary or permanent menopause and associated menopausal symptoms – most frequently vasomotoric symptoms (hot flashes, sweats), vaginal atrophy, sleep disturbances. Patients can also experience frequent decrease in bone density (osteopenia, osteoporosis), mood swings or depression, less frequently cardiac toxicity. Managements of these symptoms is complex. As hormonal replacement therapy (estrogens or combined estrogen/gestagen therapy) is contraindicated in women with breast carcinoma, other available options include non-hormonal pharmacological or non-pharmacological methods or their combinations. Women should be advised about cooling techniques and how to avoid known triggers; these measures should be combined with other non-pharmacological and pharmacological intervention. Non-pharmacological methods include the use of acupuncture or cognitive behavioral therapy. Some tips to help stay cool and decrease hot flashes – avoid hot beverages, spicy food, limit coffee or alcohol intake, dress in layers of clothing that can be removed if necessary. Pharmacological options include most frequently antidepressants – SSRI (selective serotonin reuptake inhibitor), SNRI (serotonin norepinephrin reuptake inhibitor), or alternatively gabapentin or pregabali. A very promising drug is paroxetine with a lot of clinical trials. Only this drug has FDA approval for the indication of hot flashes. Paroxetine can lead to disproportional changes in plasma levels of drug in CYP2D6 metabolism and thus it is not suitable for combination of paroxetine with tamoxifen. Several studies demonstrated the effectiveness of the newer generation of SSRI – citalopram, escitalopram, sertralin and duloxetin in ameliorating hot flashes. Venlafaxine in dose 75 or 150 mg has been associated with a 61% reduction in hot flashes frequency if compared to 27% reduction with placebo. Medroxyprogesterone acetate and megestrol acetate were investigated especially in patients with breast cancer history and both drugs demonstrate an effect in hot flashes treatment. Management of vaginal atrophy is challenging. Vaginal dryness/atrophy can be relieved with use of topical lubricants/gels or possibly in highly symptomatic patients with short term use of topical estrogens. As these symptoms require highly complex management, multidisciplinary approach is recommended.
Key words:
breast cancer – postmenopause – ovarian suppression – postmenopausal osteoporosis – therapy
This work was supported by grant of the Czech Ministry of Health – RVO (MOÚ, 00209805).
The author declares she has no potential conflicts of interest concerning drugs, products, or services used in the study.
The Editorial Board declares that the manuscript met the ICMJE recommendation for biomedical papers.
Submitted:
20. 7. 2016
Accepted:
10. 8. 2016
Zdroje
1. Elavsky S, McAuley E. Physical activity, symptoms, esteem, and life satisfaction during menopause. Maturitius 2005; 52 (3–4): 374–385.
2. Santoro N. Symptoms of menopause: hot flashes. Clin Obstet Gynecol 2008; 51 (3): 539–548. doi: 10.1097/GRF. 0b013e31818093f6.
3. Sturdee DW. The menopausal hot flash – anything new? Maturitas 2008; 60 (1): 42–49. doi: 10.1016/j.maturitas.2008.02.006.
4. Freedman RR. Physiology of hot flashes. Am J Hum Biol 2001; 13 (4): 453–464.
5. Freedman RR, Krell W. Reduced thermoregulatory null zone in postmenopausal women with hot flashes. Am J Obstet Gynecol 1999; 181 (1): 66–70.
6. Berendsen HH. The role of serotonin in hot flashes. Maturitas 2000; 36 (3): 155–164.
7. Shanafelt TD, Barton DL, Adjei AA et al. Pathophysiology and treatment of hot flashes. Mayo Clin Proc 2002; 77 (11): 1207–1218.
8. Kaplan M, Mahon S. Hot flashes management: update of the evidence for patients with cancer. Clin J Oncol Nurs 2014; 18 (6): 59–67. doi: 10.1188/14.CJON.S3.59-67.
9. Garcia MK, McQuade J, Haddad R et al. Systematic review of acupuncture in cancer care: a synthesis of the evidence. J Clin Oncol 2013; 31 (7): 952–960. doi: 10.1200/JCO.2012.43.5818.
10. Dodin S, Blanchet C, Marc I et al. Acupuncture for menopausal hot flashes. Cochrane Database Syst Rev 2013; 7: CD007410. doi: 10.1002/14651858.CD007410.pub2.
11. Walker EM, Rodriguez AI, Kohn B et al. Acupuncture versus venlafaxine for the management of vasomotor symptoms in patients with hormone receptor-positive breast cancer: a randomized controlled trial. J Clin Oncol 2010; 28 (4): 634–664. doi: 10.1200/JCO.2009.23.5150.
12. Barton DL, Loprinzi CL, Quella SK et al. J Clin Oncol 1998; 16 (2): 495–500.
13. Park H, Parker GL, Boardman CH et al. A pilot phase II trial of magnesium supplements to reduce menopausal hot flashes in breast cancer patients. Support Care Cancer 2011; 19 (6): 859–863. doi: 10.1007/s00520-011-1099-7.
14. Loprinzi CL, Michalak JC, Quella SK et al. Megestrol acetate for the prevention of hot flashes. N Engl J Med 1994; 331 (6): 347–352.
15. Quella SK, Loprinzi CL, Sloan JA et al. Long term use of megestrol acetate by cancer survivors for the treatment of hot flashes. Cancer 1998; 82 (9): 1784–1788.
16. Goodwin JW, Green SJ, Moinpour CM et al. Phase III randomized placebo-controlled trial of two doses of megestrol acetate as treatment for menopausal symptoms in women with breast cancer: SWOG Study 9626. J Clin Oncol 2008; 26 (10): 1650–1656. doi: 10.1200/JCO.2006.10.6179.
17. Bertelli GB, Venturini M, Del Mastro M et al. Intramuscular depot medoxyprogesterone versus oral megestrol for the control of postmenopausal hot flashes in breast cancer patients: a randomized study. Ann Oncol 2002; 13 (6): 883–888.
18. Loprinzi CL, Kugler JW, Sloan JA et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet 2000; 356 (9247): 2059–2063.
19. Carpenter JS, Storniolo AM, Johns S et al. Randomized, double-blind, placebo controlled crossover trial sof venlafaxine for hot flashes after breast cancer. Oncologist 2007; 12 (1): 124–135.
20. Buijs C, Mom CH, Willemse PH et al. Venlafaxine versus clonidine for the treatment of hot flashes in breast cancer patients: a double-blind, randomized cross-over study. Breast Cancer Res Treat 2009; 115 (3): 573–580. doi: 10.1007/s10549-008-0138-7.
21. Bordeleau L, Pritchard KI, Loprinzi CL et al. Multicenter, randomized, cross-over clinical trial of venlafaxine versus gabapentin for the management of hot flashes in breast cancer survivors. J Clin Oncol 2010; 28 (35): 5147–5152. doi: 10.1200/JCO.2010.29.9230.
22. Speroff L, Gass M, Constantine G et al. Efficacy and tolerability of desvenlafaxin succinate treatment for menopausal vasomotor symptoms: a randomized controlled trial. Obstet Gynecol 2008; 111 (1): 77–87. doi: 10.1097/01.AOG.0000297371.89129.b3.
23. Archer DF, Dupont CM, Comstantine GD et al. Desvenlafaxine for the treatment of vasomotor symtpoms associated with menopause: a double-blind, randomized, placebo-controlled trial of efficacy and safety. Am J Obstet Gynecol 2009; 200 (3): 238. doi: 10.1016/j.ajog.2008.10. 057.
24. Archer DF, Seidman L, Constantine GD et al. A double-blind, randomly assigned, placebo-controlled study of desvenlafaxine efficacy and safety for the treatment of vasomotor symptoms associated with menopause. Am J Obstet Gynecol 2009; 200 (2): 172. doi: 10.1016/j.ajog.2008.09.877.
25. Bouchard P, Panay N, de Villiers TJ et al. Randomized placebo- and active-controlled study of desvenlafaxine for menopausal vasomotor symptoms. Climacteric 2012; 15 (1): 12–20. doi: 10.3109/13697137.2011.586445.
26. Freeman MP, Hirchsberg AM, Wang B et al. Duloxetin for major depressive disorders and daytime and nighttime hot flashes associated with me noapusal transition. Maturitas 2013; 75 (2): 170–174. doi: 10.1016/j.maturitas.2013.03.007.
27. Simon JA, Portman DJ, Kaunitz AM et al. Low-dose paroxetine 7,5 mg for menopausal vasomotor symptoms: two randomized controlled trials. Menopause 2013; 20 (10): 1027–1035. doi: 10.1097/GME.0b013e3182a66aa7.
28. Soares CB, Joffe H, Viguera AC et al. Paroxetine versus placebo for women in midlife after hormone discontinuation. Am J Med 2008; 121 (2): 159–162. doi: 10.1016/j.amjmed.2007.10.007.
29. Stearns V, Beebe KL, Iyengar M et al. Paroxetine controlled repase in the treatment of menopausal hot flashes: a randomized controlled trial. JAMA 2003; 289 (21): 2827–2834.
30. Stearns V, Isaacs C, Rowland J et al. A pilot trial assessing the efficacy of paroxetine hydrochloride in controlling hot flashes in breast cancer survivors. Ann Oncol 2000; 11 (1): 17–22.
31. Weitzner M, Moncello J, Jacobsen PB et al. A pilot trial of paroxetine for the treatment of hot flashes and associated symptoms in women with breast cancer. J Pain Symtpom Manage 2002; 23 (4): 337–345.
32. Stearns V, Slack R, Greep N et al. Paroxetine is an effective treatment for hot flashes: results from a prospective randomized clinical trial. J Clin Oncol 2005; 23 (28): 6919–6930.
33. Stearns V, Johnson MD, Rae JM et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 2003; 95 (23): 1758–1764.
34. Grady D, Cohen B, Tice J et al. Ineffectiveness of sertraline for treatment of menopausal hot flashes: a randomized controlled trial. Obstet Gynecol 2007; 109 (4): 823–830.
35. Gordon PR, Kerwin JP, Boesen KG et al. Sertraline to treat hot flashes: a randomized controlled, double blind, crossover trial in a general population. Menopause 2006; 13 (4): 568–575.
36. Aedo S, Cavada G, Campodonico I et al. Sertraline improves static and psychological symptoms of the climacteric syndrome. Climacteric 2011; 14 (5): 590–595. doi: 10.3109/13697137.2011.568645.
37. Kimmick GG, Lovato J, McQuellon R et al. Randomized, double-blind, placebo-controlled, crossover study of sertraline for the treatment of hot flashes in women with early stage breast cancer taking tamoxifen. Breast J 2006; 12 (2): 114–122.
38. Wu MF, Hilsenbeck SG, Tham YL et al. The efficacy of sertraline for controlling hot flashes in women with or at high risk of developing breast cancer. Breast Cancer Res Treat 2009; 118 (2): 369–375.
39. Loprinzi CL, Sloan JA, Perez EA et al. Phase III evaluation of fluoxetine for treatment of hot flashes. J Clin Oncol 2002; 20 (6): 1578–1583.
40. Suvanto-Luukkonen E, Koivunen R, Sundström H et al. Citalopram and fluoxetine in the treatment of postmenopausal symptoms: a prospective, randomized, 9-month, placebo-controlled, double-blind study. Menopause 2005; 12 (1): 18–26.
41. Barton DL, Atherton PJ, Bauer BA et al. Pilot evaluation of citalopram for the reliéf of hot flashes. J Support Oncol 2003; 1 (1): 37–51.
42. Loprinzi CL, Flynn PJ, Carpenter LA et al. Pilot evaluation of citalopram for the treatment of hot flashes in women with inadequate benefit from venlafaxine. J Palliat Med 2005; 8 (5): 924–930.
43. Kalay AE, Demir B, Haberal A et al. Efficacy of citalopram on climacteric symptoms. Menopause 2007; 14 (2): 223–229.
44. Barton DL, LaVasseur BI, Sloan JA et al. Phase III, placebo-controlled trial o free doses of citalopram for the treatment of hot flashes: NCCTG trial N05C9. J Clin Oncol 2008; 26 (20): 953.
45. Freeman EW, Guthrie KA, Caan B et al. Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial. JAMA 2011; 305 (3): 267–274. doi: 10.1001/jama.2010.2016.
46. Freedman RR, Kruger ML, Tancer ME et al. Escitalopram treatment of menopausal hot flashes. Menopausa 2011; 18 (8): 893–896. doi: 10.1097/gme.0b013e31820ccae9.
47. Loprinzi CL. Pilot evaluation of gabapentin for treating hot flashes. Mayo Clin Proc 2002; 77 (11): 1159–1163.
48. Guttuso T Jr, Kurlan R, McDermott MP et al. Gabapentin’s effect on hot flashes in postmenoapusal women: a randomized controlled trial. Obstet Gynecol 2003; 101 (2): 337–345.
49. Pandya KJ, Morrow GR, Roscoe JA et al. Gabapentin for hot flashes in 420 women with breast cancer: a randomized double-blind placebo-controlled trial. Lancet 2005; 366 (9488): 818–824.
50. Reddy SY, Warner Hm, Guttuso T Jr et al. Gabapentin, estrogen and placebo for treating hot flashes: a randomized controlled trial. Obstet Gynecol 2006; 108 (1): 41–48.
51. Butt DA, Lock M, Lewis JE et al. Gabapentin for the treatment of menopausal hot falshes: a randomized controlled trial. Menopause 2008; 15 (2): 310–318.
52. Loprinzi CL, Qin R, Balcueva EP et al. Phase III, randomized, double-blind, placebo-controlled evaluation of pregabalin for alleviating hot flashes, N07C1. J Clin Oncol 2010; 28 (4): 641–647. doi: 10.1200/JCO.2009.24.5647.
53. Castelo-Branco C, Cancelo MJ, Villero J et al. Management of post-menopausal vaginal atrophy and atrophic vaginitis. Matutitas 2005; 52 (Suppl 1): S46–S52.
54. Derzko C, Elliott S, Lam W. Management of sexual dysfunction in postmenopausal breast cancer pacients taking adjuvant aromatase inhibitor therapy. Curr Oncol 2007; 14 (Suppl 1): S20–S40.
55. Kendall A, Dowsett M, Folkerd E et al. Caution: vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors. Ann Oncol 2006; 17 (4): 584–587.
56. Gilbert E, Ussher JM, Perz J. Sexuality after breast cancer: a review. Maturitas 2010; 66 (4): 397–407. doi: 10.1016/j.maturitas.2010.03.027.
57. Ganz PA, Desmond KA, Belin TR et al. Predcitors of sexual health in women after a breast cancer diagnosis. J Clin Oncol 1999; 17 (8): 2371–2380.
58. Rosen R, Brown C, Heiman J et al. The female sexual function index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther 2000; 26 (2): 191–208.
59. Bokmand S, Flyger H. Acupuncture relieves menopausal discomfort in breast cancer patients: a prospective, double-blind, randomized study. Breast 2013; 22 (3): 320–323. doi: 10.1016/j.breast.2012.07.015.
60. Walker EM, Rodriguez AI, Kohn B et al. Acupuncture versus venlafaxine for the management of vasomotor symptoms in patients with hormone receptor-positive breast cancer: a randomized controlled trial. J Clin Oncol 2010; 28 (4): 634–640. doi: 10.1200/JCO.2009.23.5150.
61. Carpenter JS, Neal JG, Payne J et al. Cognitive-behavioral intervention for hot flashes. Oncol Nurs Forum 2007; 34 (1): 37.
62. Hunter MS, Coverntry S, Hamed H et al. Evaluation of a group cognitive behavioral intervention for women suffering from menopausal symptoms following breast cancer treatment. Psychooncology 2009; 18 (5): 560–563. doi: 10.1002/pon.1414.
63. Marshall-McKenna R, Morrison A, Stirling L et al. A randomized trial of the cool pad pillow topper versus standard care for sleep disturbance and hot flashes in women on endocrine therapy for breast cancer. Support Care Cancer 2016; 24 (4): 1821–1829. doi: 10.1007/s00520-015-2967-3.
64. Suvanto-Luukonen E, Koivunen R, Sundstrom H et al. Citalopram and fluoxetine in the treatment of postmenopausal symptoms: a prospective, randomized, 9-month, placebo-controlled, double-blind study. Menopause 2005; 12 (1): 18–26.
65. Stearns V, Beebe KL, Iyengar M et al. Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial. JAMA 2003; 289 (21): 2827–2834.
66. Ensrud KE, Hadine J, Guthrie K et al. Effect of escitalopram on insomnia symptoms and subjective sleep quality in healthy menopausal women with hot flashes: a randomized controlled trial. Menopause 2012; 19 (8): 848–855.
67. Nystedt M, Berglund G, Bolund C et al. Side effects of adjuvant endocrine treatment in premenopausal breast cancer patients: a prospective randomized study. J Clin Oncol 2003; 21 (9): 1836–1844.
68. Phillips KA, Feng Y, Ribi K et al. Co-SOFT: the cognitive function sub-study of the suppression of ovarian function trial (SOFT). SABCS December 2014; San Antonio, TX.
69. Pagani O, Regan MM, Walley BA et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med 2014; 371 (2): 107–118. doi: 10.1056/NEJMoa1404037.
70. Koopal C, Janssen-Heijnen ML, van de Wouw AJ et al. Fracture incidence in pre- and postmenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer. J Clin Oncol 2008; 26: 4739–4745.
71. Francis PA, Regan MM, Fleming GF et al. Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med 2015; 372 (5): 436–446. doi: 10.1056/NEJMoa1412379.
Štítky
Paediatric clinical oncology Surgery Clinical oncologyČlánok vyšiel v časopise
Clinical Oncology
2016 Číslo Supplementum 3
- Spasmolytic Effect of Metamizole
- Metamizole at a Glance and in Practice – Effective Non-Opioid Analgesic for All Ages
- Metamizole in perioperative treatment in children under 14 years – results of a questionnaire survey from practice
- Current Insights into the Antispasmodic and Analgesic Effects of Metamizole on the Gastrointestinal Tract
- Obstacle Called Vasospasm: Which Solution Is Most Effective in Microsurgery and How to Pharmacologically Assist It?
Najčítanejšie v tomto čísle
- Treatment with Aromatase Inhibitors in Postmenopausal Women with Breast Cancer and the Possibility of Influencing Side Effects
- Breast Cancer – Specifics of Gynecological Care and Counseling
- Circulating Levels of Estradiol in Breast Cancer Patients Treated with Aromatase Inhibitors and Their Clinical Implications
- Pregnancy after Treatment of Breast Cancer